Evaluation of crizotinib absolute bioavailability, the bioequivalence of three oral formulations, and the effect of food on crizotinib pharmacokinetics in healthy subjects-Reference-Cited by-同舟云学术

Evaluation of crizotinib absolute bioavailability, the bioequivalence of three oral formulations, and the effect of food on crizotinib pharmacokinetics in healthy subjects

Published:2014-07-11 Issue:1 Volume:55 Page:104-113
ISSN:0091-2700
Container-title:The Journal of Clinical Pharmacology
language:en
Short-container-title:The Journal of Clinical Pharmacology

Author:

Xu Huiping¹,O'Gorman Melissa²,Boutros Tanya¹,Brega Nicoletta³,Kantaridis Constantino⁴,Tan Weiwei¹,Bello Akintunde⁵

Affiliation:

1. Pfizer Inc.; La Jolla CA USA

2. Pfizer Inc.; Groton CT USA

3. Pfizer Inc.; Milan Italy

4. Pfizer Inc.; Brussels Belgium

5. Pfizer Inc.; New York NY USA

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Reference12 articles.

1. Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: sobering results;Breathnach;J Clin Oncol,2001

2. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib;Lynch;N Engl J Med,2004

3. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy;Paez;Science,2004

4. EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib;Pao;Proc Natl Acad Sci USA,2004

5. United States Food and Drug Administration Drug Approval summary: Gefitinib (ZD1839; Iressa) tablets;Cohen;Clin Cancer Res,2004

Cited by 39 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Avelumab in Combination With Lorlatinib or Crizotinib in Patients With Previously Treated Advanced NSCLC: Phase 1b/2 Results From the JAVELIN Lung 101 Trial;JTO Clinical and Research Reports;2024-07

2. Crizotinib inhibits the metabolism of tramadol by non-competitive suppressing the activities of CYP2D1 and CYP3A2;PeerJ;2024-05-30

3. Evaluation of Solubility-Limited Absorption as a Surrogate to Predicting Positive Food Effect of Bcs Ii/Iv Drugs;2024

4. The Importance of Drug Interactions During ALK Tyrosine Kinase Inhibitor Therapies;Interdisciplinary Cancer Research;2024

5. Pharmacology of Tyrosine Kinase Inhibitors;Clinical Journal of the American Society of Nephrology;2023-12-11